Content
January 2010, Volume 10, Issue 1
- 91-98 Colorectal cancer in Russia
by Maria Avksentyeva - 99-105 Colorectal cancer in Turkey: current situation and challenges for the future
by Mehtap Tatar & Fahreddin Tatar - 107-114 Colorectal cancer in Mexico: should a middle income country invest in screening or in treatment?
by Emma Verastegui & Alejandro Mohar - 115-129 The dynamics of colorectal cancer management in 17 countries
by Panos Kanavos & Willemien Schurer
October 2009, Volume 10, Issue 4
- 357-359 Ten arguments for a societal perspective in the economic evaluation of medical innovations
by Bengt Jönsson - 361-369 The socioeconomic costs of mental illness in Spain
by Juan Oliva-Moreno & Julio López-Bastida & Angel Montejo-González & Rubén Osuna-Guerrero & Beatriz Duque-González - 371-388 Can Mediterranean diet really influence obesity? Evidence from propensity score matching
by Andreas Drichoutis & Panagiotis Lazaridis & Rodolfo Nayga - 389-397 Importance of sociodemographic and morbidity aspects in measuring health-related quality of life: performances of three tools
by Cecilia Quercioli & Gabriele Messina & Emanuela Barbini & Giovanni Carriero & Mara Fanì & Nicola Nante - 399-407 GPs as citizens’ agents: prescription behavior and altruism
by Kim Olsen & Dorte Gyrd-Hansen & Andreas Boegh & Sofie Hansen - 409-419 Estimating the cost related to surveillance of colorectal cancer in a French population
by Catherine Lejeune & Christine Binquet & Franck Bonnetain & Amel Mahboubi & Michal Abrahamowicz & Thierry Moreau & Maria Raikou & Laurent Bedenne & Catherine Quantin & Claire Bonithon-Kopp - 421-428 Perceived job security and sickness absence: a study on moral hazard
by Jahangir Khan & Clas Rehnberg - 429-436 The lack of theoretical support for using person trade-offs in QALY-type models
by Lars Østerdal - 437-453 Contractual design and PPPs for hospitals: lessons for the Portuguese model
by Pedro Barros & Xavier Martinez-Giralt - 455-465 Alcohol and labor supply: the case of Iceland
by Tinna Asgeirsdottir & Kerry McGeary - 467-474 Private expenditure and the role of private health insurance in Greece: status quo and future trends
by Olga Siskou & Daphne Kaitelidou & Charalampos Economou & Peter Kostagiolas & Lycourgos Liaropoulos
July 2009, Volume 10, Issue 3
- 239-242 Why the econometrician is in good spirits: a workshop through the looking glass
by Carl Lyttkens - 243-254 Exploring spatial patterns in general practice expenditure
by Mickael Bech & Jørgen Lauridsen - 255-265 Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study
by Douglas Taylor & Ankur Pandya & David Thompson & Paula Chu & Jennifer Graff & James Shepherd & Nanette Wenger & Heiner Greten & Rafael Carmena & Michael Drummond & Milton Weinstein - 267-273 Cost of skin cancer in England
by S. Morris & B. Cox & N. Bosanquet - 275-285 The economic costs of Group B Streptococcus (GBS) disease: prospective cohort study of infants with GBS disease in England
by Elizabeth-Ann Schroeder & Stavros Petrou & Gail Balfour & Oya Edamma & Paul Heath - 287-297 The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals
by Ansgar Resch & Michael Wilke & Christian Fink - 299-308 Hybrid risk adjustment for pharmaceutical benefits
by Manuel García-Goñi & Pere Ibern & José Inoriza - 309-321 Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach
by Bastian Haß & Juliane Lungershausen & Nadine Hertel & Barbara Poulsen Nautrup & Wioletta Kotowa & Hiltrud Liedgens - 323-328 Material versus social deprivation and health: a case study of an urban area
by Angela Testi & Enrico Ivaldi - 329-336 Modelling health expenditure at the household level in Greece
by Manos Matsaganis & Theodore Mitrakos & Panos Tsakloglou - 337-346 Total costs of injury from accidents in the home and during education, sports and leisure activities: estimates for Norway with assessment of uncertainty
by Knut Veisten & Åse Nossum & Juned Akhtar - 347-355 The economics of cochlear implant management in France: a multicentre analysis
by Laurent Molinier & Hélène Bocquet & Vanina Bongard & Bernard Fraysse
May 2009, Volume 10, Issue 2
- 121-123 Is there a “continental” view of health economics evaluation?
by Claude Pen - 125-133 Pesticides and farmer health in Nicaragua: a willingness-to-pay approach to evaluation
by Hildegard Garming & Hermann Waibel - 135-148 The income distributive implications of recent private health insurance policy reforms in Australia
by Alfons Palangkaraya & Jongsay Yong & Elizabeth Webster & Peter Dawkins - 149-155 International comparison of orthotic brace prices
by Steven Simoens & Paul Guillaume & Ingrid Moldenaers & Antony Depoorter & Sandra Coster & Dirk den Steen & Stefaan Sande & Hans Debruyne & Dirk Ramaekers & Murielle Lona - 157-165 Guidelines for completing the EURONHEED transferability information checklists
by John Nixon & Stephen Rice & Michael Drummond & Stephanie Boulenger & Philippe Ulmann & Gerard Pouvourville - 167-178 The labor supply of registered nurses in Finland: the effect of wages and working conditions
by T. Kankaanranta & P. Rissanen - 179-186 Patient characteristics and fairness
by Hannu Valtonen - 187-196 Can we assume that research participants are utility maximisers?
by Gethin Griffith & Val Morrison & J. Williams & Rhiannon Edwards - 197-206 Activity-based funding for National Health Service hospitals in England: managers’ experience and expectations
by Jonathan Sussex & Shelley Farrar - 207-215 Quality choice in a health care market: a mixed duopoly approach
by Yasuo Sanjo - 217-226 Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort
by Ulf-Göran Gerdtham & L. Andersson & Åsa Ericsson & Sixten Borg & Sven-Arne Jansson & Eva Rönmark & Bo Lundbäck - 227-231 Factors affecting nurses’ decision to get the flu vaccine
by Shosh Shahrabani & Uri Benzion & Gregory Yom Din - 233-236 Response to the expertise: Procedures and methods of benefit assessments for medicines in Germany, by Geertruida E. Bekkering and Jos Kleijnen
by Klaus Koch & Stefan Lange - 237-238 Procedures and methods of benefit assessments for medicines in Germany: give the child a name
by Holger Schünemann & Regina Kunz & Yngve Falck-Ytter & Nancy Santesso
February 2009, Volume 10, Issue 1
- 1-3 Can we afford to ignore missing data in cost-effectiveness analyses?
by Andrea Marshall & Lucinda Billingham & Stirling Bryan - 5-13 Health care costs, work productivity and activity impairment in non-malignant chronic pain patients
by Christian Kronborg & Gitte Handberg & Flemming Axelsen - 15-23 SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility
by Richard Grieve & Marina Grishchenko & John Cairns - 25-38 Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects
by Christa Claes & Ralf Reinert & Johann-Matthias Schulenburg - 39-45 Comparing methodologies for the cost estimation of hospital services
by S. Tan & F. Rutten & B. Ineveld & W. Redekop & L. Hakkaart-van Roijen - 47-55 Cost utility analysis of knee prosthesis with complete microprocessor control (C-leg) compared with mechanical technology in trans-femoral amputees
by Simone Gerzeli & Aleksandra Torbica & Giovanni Fattore - 57-63 The relationship between the Balanced Budget Act and length of stay for Medicare patients in US hospitals
by Mustafa Younis & Dana Forgione - 65-79 Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany
by Dirk Schürmann & Sonja Sorensen & Erwin Cock & Sandeep Duttagupta & Ansgar Resch - 81-91 A comparison between willingness to pay and willingness to give up time
by Debby Helvoort-Postulart & Carmen Dirksen & Alfons Kessels & Jos Engelshoven & M. Myriam Hunink - 93-101 The quality of life of Palestinians living in chronic conflict: assessment and determinants
by Awad Mataria & Rita Giacaman & Angelo Stefanini & Nirmala Naidoo & Paul Kowal & Somnath Chatterji - 103-109 Do quality-adjusted life years take account of lost income? Evidence from an Australian survey
by Jeff Richardson & Stuart Peacock & Angelo Iezzi - 111-119 An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event
by Manouchehr Tavakoli & Neil Pumford & Mark Woodward & Alex Doney & John Chalmers & Stephen MacMahon & Ronald MacWalter
November 2008, Volume 9, Issue 4
- 311-312 Health technology assessment: for whom the bell tolls?
by Livio Garattini & Gianluigi Casadei - 313-323 Decision-analytical modelling in health-care economic evaluations
by Xin Sun & Thomas Faunce - 325-331 Discarded cellular components and the technical efficiency of component preparation
by Marketta Veihola & Pekka Aroviita & Riitta Kekomäki & Miika Linna & Harri Sintonen - 333-342 Nurses’ intentions to leave nursing in Finland
by T. Kankaanranta & P. Rissanen - 343-349 Lessons for health care reform from the less developed world: the case of the Philippines
by Konrad Obermann & Matthew Jowett & Juanito Taleon & Melinda Mercado - 351-360 The societal cost of alcohol consumption: an estimation of the economic and human cost including health effects in Sweden, 2002
by Johan Jarl & Pia Johansson & Antonina Eriksson & Mimmi Eriksson & Ulf-G. Gerdtham & Örjan Hemström & Klara Selin & Leif Lenke & Mats Ramstedt & Robin Room - 361-367 Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France
by Laurence Clerc & Valérie Jooste & Catherine Lejeune & Bernard Schmitt & Patrick Arveux & Catherine Quantin & Jean Faivre & Anne-Marie Bouvier - 369-380 Health insurance theory: the case of the missing welfare gain
by John Nyman - 381-384 Economic evaluation of innovative technologies in health care should include a short-run perspective
by Eddy Adang - 385-392 Public funding for community-based skilled delivery care in Indonesia: to what extent are the poor benefiting?
by Tim Ensor & Mardiati Nadjib & Zahid Quayyum & Amila Megraini - 393-403 Expanding access to primary care without additional budgets? A case study from Burkina Faso
by Paul Marschall & Steffen Flessa - 405-416 Redistributive effects in public health care financing
by Ivonne Honekamp & Daniel Possenriede
August 2008, Volume 9, Issue 3
- 205-207 IQWiG: an opportunity lost?
by Bengt Jönsson - 209-219 Quality of life and cost-effectiveness of acupuncture treatment in patients with osteoarthritis pain
by Thomas Reinhold & Claudia Witt & Susanne Jena & Benno Brinkhaus & Stefan Willich - 221-228 Economic consequences of near-patient test results: the case of tests for the Helicobacter Pylori bacterium in dyspepsia
by Siri Fauli & Geir Thue - 229-236 The cost of treating high blood pressure in general practice in France
by Yaël Tibi-Levy & Gérard Pouvourville & Jérémie Westerloppe & Marion Bamberger - 237-249 An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions
by Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir - 251-259 Estimating the expected value of partial perfect information: a review of methods
by Doug Coyle & Jeremy Oakley - 261-264 Choice determinants of the mobility in the Dutch health insurance market
by Ilaria Mosca & Anoushka Schut-Welkzijn - 265-274 Predisposing factors for early retirement in patients with Schizophrenia in Germany
by Reinhard Schnabel & Heiko Friedel & Andreas Erfurth & Matthias Angermayer & Johannes Clouth & Florian Eichmann - 275-284 Preferences and utilities for the symptoms of moderate to severe allergic asthma
by Andrew Lloyd & Scott Doyle & Sarah Dewilde & Florian Turk - 285-292 In pursuit of QALY weights for relatives: empirical estimates in relatives caring for older people
by Thomas Davidson & Barbro Krevers & Lars-Åke Levin - 293-304 A theoretical and empirical investigation of nutritional label use
by Andreas Drichoutis & Panagiotis Lazaridis & Rodolfo Nayga & Maria Kapsokefalou & George Chryssochoidis - 305-310 Pricing and reimbursement of pharmaceuticals in Italy
by Pietro Folino-Gallo & Simona Montilla & Mario Bruzzone & Nello Martini
May 2008, Volume 9, Issue 2
- 99-101 The CHESME Health Economic Evaluations Database (CHESME HEED) project
by Dimitrios Rovithis & Lycurgus Liaropoulos - 103-115 Costing maternal health services in South Tanzania
by Claudia Both & Albrecht Jahn & Steffen Fleßa - 117-125 Primary physicians’ response to changes in fees
by Jostein Grytten & Fredrik Carlsen & Irene Skau - 127-136 The search for good compliance: economic aspects of a conveyed combination pharmaco-therapy, exemplified by an osteoporosis therapy
by Peter Oberender & Jürgen Zerth - 137-145 Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD
by Susan Griffin & Helen Weatherly & Gerry Richardson & Mike Drummond - 147-156 The role of non-need factors in individual GP utilisation analysis and their implications for the pursuance of equity: a cross-country comparison
by P. McGregor & P. McKee & C. O’Neill - 157-163 Eligibility for free GP care, “need” and GP visiting in Ireland
by A. Nolan & B. Nolan - 165-170 Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial
by Hans Janka & Barbara Högy - 171-183 Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
by Jonathan Karnon & Thomas Delea & Vicki Barghout - 185-191 The impact of generic substitution on price competition in Finland
by Ville Aalto-Setälä - 193-201 Spillover of cause-specific longevity interventions: an independent mortality risk model
by Liqun Liu - 203-203 Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance
by Barbara Högy & Heinz-Otto Keinecke & Michael Borte
November 2008, Volume 9, Issue 1
- 1-3 Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy
by Thomas Müller - 5-29 Procedures and methods of benefit assessments for medicines in Germany
by Geertruida Bekkering & Jos Kleijnen - 31-43 Biostatistical aspects for the use of evidence based medicine in health technology assessment
by Nick Freemantle
February 2008, Volume 9, Issue 1
- 1-6 Alcohol consumption in the EU: health economics and policy issues under a permanent debate
by Fernando Antoñanzas & Roberto Rodríguez-Ibeas & Emilio Barco & Manuel Ramírez & Mariola Pinillos - 7-15 Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects
by Adam Lloyd & Nishma Patel & David Scott & Claus Runge & Christa Claes & Markus Rose - 17-22 Estimation and comparison of ostomy appliance costs with tariffs in Belgium
by Veerle Vanleene & Luc Maré & Ingrid Moldenaers & Hans Debruyne & Steven Simoens & Dirk Steen & Dirk Ramaekers - 23-32 Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia
by Ramon Sabes-Figuera & José Segú & Jaume Puig-Junoy & Antoni Torres - 33-39 Vaccination versus “wait and treat”: how to subsidize them?
by Louis Eeckhoudt & Maurice Marchand & Pierre Pestieau & Gwenaël Piaser - 41-50 The differences in characteristics between health-care users and non-users: implication for introducing community-based health insurance in Burkina Faso
by Hengjin Dong & Adjima Gbangou & Manuela Allegri & Subhash Pokhrel & Rainer Sauerborn - 51-61 Work environment satisfaction and employee health: panel evidence from Denmark, France and Spain, 1994–2001
by Nabanita Datta Gupta & Nicolai Kristensen - 63-67 Does greater exposure to own-health data make a difference on the visual analog scale?
by Amir Shmueli & David Messika & Havi Murad & Laurence Freedman - 69-78 Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone
by Jose-Luis Pinto-Prades & Veronica Farreras & Jaime de Bobadilla - 79-86 Factors influencing hospital costs of lung cancer patients in Northern Ireland
by Ian Fleming & Pauline Monaghan & Anna Gavin & Ciaran O’Neill - 87-97 Pharmaceutical pricing and reimbursement reforms in Greece
by John Yfantopoulos
January 2008, Volume 8, Issue 2
- 33-34 Patient access to rheumatoid arthritis treatments
by Bengt Jönsson & Gisela Kobelt & Josef Smolen - 35-38 Patient access to rheumatoid arthritis treatments
by Bengt Jönsson - 39-47 The burden of rheumatoid arthritis and access to treatment: a medical overview
by J. Smolen & D. Aletaha - 49-60 The burden of rheumatoid arthritis and access to treatment: health burden and costs
by J. Lundkvist & F. Kastäng & G. Kobelt - 61-86 The burden of rheumatoid arthritis and access to treatment: uptake of new therapies
by B. Jönsson & G. Kobelt & J. Smolen - 87-93 The burden of rheumatoid arthritis and access to treatment: determinants of access
by J. Lundqvist & F. Kastäng & G. Kobelt & B. Jönsson - 95-106 The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments
by G. Kobelt & B. Jönsson
December 2007, Volume 8, Issue 4
- 301-304 Tobacco policies in the European Union: a need for state and continental harmonisation?
by Fernando Antoñanzas & Roberto Rodríguez - 305-312 Foreign direct investment in the health care sector and most-favoured locations in developing countries
by J. Outreville - 313-323 Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery
by Jonas Lundkvist & David Bergqvist & Bengt Jönsson - 325-332 The impact of home hospitalization on healthcare costs of exacerbations in COPD patients
by Jaume Puig-Junoy & Alejandro Casas & Jaume Font-Planells & Joan Escarrabill & Carme Hernández & Jordi Alonso & Eva Farrero & Gemma Vilagut & Josep Roca - 333-337 Pricing matrix model: dealing with uncertainty
by Mark Nuijten - 339-346 The incidence and cost of cardiac surgery adverse events in Australian (Victorian) hospitals 2003–2004
by Jonathon Ehsani & Stephen Duckett & Terri Jackson - 347-357 Assessment of the pharmaceutical market in Poland after accession to the European Union
by Patricia Willert - 359-359 Costs and quality of life in multiple sclerosis in The Netherlands
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Bert Anten & Mattias Ekman & Peter Jongen & Chris Polman & Bernard Uitdehaag
September 2007, Volume 8, Issue 3
- 179-179 Editor’s note
by J.-Matthias Graf von der Schulenburg & Wolfgang Greiner - 181-193 Innovation in hospitals: a survey of the literature
by Faridah Djellal & Faïz Gallouj - 195-212 Risk adjustment policy options for casemix funding: international lessons in financing reform
by Kathryn Antioch & Randall Ellis & Steve Gillett & Daniel Borovnicar & Ric Marshall - 213-223 Incorporating efficiency in hospital-capacity planning in Germany
by Ludwig Kuntz & Stefan Scholtes & Antonio Vera - 225-236 Variations in activity and practice patterns: a French study for GPs
by Sophie Béjean & Christine Peyron & Renaud Urbinelli - 237-243 Income-related health inequality in Belgium: a longitudinal perspective
by Ann Lecluyse - 245-251 Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners
by Ariel Berger & Piotr Kramarz & Gry Kopperud & John Edelsberg & Gerry Oster - 253-266 Patient access to pharmaceuticals: an international comparison
by Joshua Cohen & Laura Faden & Susan Predaris & Brian Young - 267-277 Supplier-induced demand: re-examining identification and misspecification in cross-sectional analysis
by Stuart Peacock & Jeffrey Richardson - 279-285 Is there an association between economic performance and public satisfaction in health care?
by Eddy Adang & George Borm - 287-295 Why do patients bypass the nearest hospital? An empirical analysis for orthopaedic care and neurosurgery in the Netherlands
by Marco Varkevisser & Stéphanie Geest - 297-300 Economic aspects of the new Spanish laws on pharmaceutical preparations
by Fernando Antoñanzas & Juan Oliva & Mariola Pinillos & Carmelo Juàrez
June 2007, Volume 8, Issue 2
- 83-88 The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience
by László Gulácsi - 89-95 Pharmacoeconomic studies in Italy: a critical review of the literature
by D. Cornago & L. Li Bassi & P. Compadri & L. Garattini - 97-103 The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management
by Vesna Bjegovic & Zorica Terzic & Jelena Marinkovic & Nebojsa Lalic & Sandra Sipetic & Ulrich Laaser - 105-110 Patients’ willingness to pay for electronic communication with their general practitioner
by Trine Bergmo & Silje Wangberg - 111-121 Systematic review of economic evaluations and cost analyses of guideline implementation strategies
by Luke Vale & Ruth Thomas & Graeme MacLennan & Jeremy Grimshaw - 123-135 Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain
by Maureen Rutten-van Mölken & Jan Oostenbrink & Marc Miravitlles & Brigitta Monz - 137-144 The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49
by Richard Norman & D. Evans & Douglas Easton & Kenneth Young - 145-151 Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system
by K. Le Lay & E. Myon & S. Hill & L. Riou-Franca & D. Scott & M. Sidhu & D. Dunlop & R. Launois - 153-160 An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany
by Sara Sheriff & K. Petry & Hans Ikenberg & Geoffrey Crouse & Peter Mazonson & Christopher Santas - 161-168 Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis
by Andrew Palmer & William Valentine & Joshua Ray & Stephane Roze & Noemi Muszbek - 169-170 Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi
by Joshua Cohen - 171-171 Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen
by Livio Garattini - 173-177 Discussion point: should governments buy drug patents?
by Juan Llano
March 2007, Volume 8, Issue 1
- 1-3 Should we really worry about “launch delays” of new drugs in OECD countries?
by Livio Garattini & Simone Ghislandi - 5-15 Cost of breast cancer in Sweden in 2002
by Mathias Lidgren & Nils Wilking & Bengt Jönsson - 17-24 Better primary physician services lead to fewer hospital admissions
by Fredrik Carlsen & Jostein Grytten & Julie Kjelvik & Irene Skau - 25-30 Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy
by Peter Lindgren & Thomas Kahan & Neil Poulter & Martin Buxton & Patrick Svarvar & Björn Dahlöf & Bengt Jönsson - 31-39 Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set
by Corinne Behrend & Florian Buchner & Michael Happich & Rolf Holle & Peter Reitmeir & Jürgen Wasem - 41-50 Long-term absenteeism due to sickness in Sweden. How long does it take and what happens after?
by Daniela Andrén - 51-57 Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany
by B. Brüggenjürgen & P. Lindgren & B. Ehlken & H.-J. Rupprecht & S. Willich - 59-65 A multilevel analysis on the determinants of regional health care expenditure: a note
by Guillem López-Casasnovas & Marc Saez - 67-76 Resource use and costs associated with patients treated for depression in primary care
by P. Sobocki & M. Ekman & H. Ågren & I. Krakau & B. Runeson & B. Mårtensson & B. Jönsson - 77-82 A public–private analysis of the new Dutch health insurance system
by Hans Maarse & Yvette Bartholomée
September 2007, Volume 8, Issue 1
- 1-2 Economic evaluation for pharmaceuticals in Germany
by Bengt Jönsson - 3-3 Technology assessment in the German context
by Michael Drummond - 5-31 Methods for determining cost-benefit ratios for pharmaceuticals in Germany
by J.- Graf v. d. Schulenburg & Christoph Vauth & Thomas Mittendorf & Wolfgang Greiner
December 2006, Volume 7, Issue 4
- 223-224 Time for a common standard for cost-effectiveness in Europe?
by Bengt Jönsson - 225-230 Optional deductibles in social health insurance systems
by Claudia Pütz & Christian Hagist - 231-237 A decomposition of income-related health inequality applied to EQ-5D
by Jens Gundgaard & Jørgen Lauridsen - 238-246 Cost effectiveness of preventive home visits to the elderly
by Christian Kronborg & Mikkel Vass & Jørgen Lauridsen & Kirsten Avlund - 247-254 Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction
by A. Gerber & T. Evers & H. Haverkamp & K. Lauterbach - 255-264 Cost-effectiveness of the Danish smoking cessation interventions
by Kim Olsen & Lone Bilde & Henrik Juhl & Niels Kjaer & Holger Mosbech & Torben Evald & Mette Rasmussen & Helle Hiladakis - 265-269 The demand for private health care under national health insurance
by Y. Machnes - 270-275 Economic cost associated with type II diabetes in Spanish patients
by Miguel Ballesta & Florentino Carral & Gabriel Olveira & José Girón & Manuel Aguilar - 276-284 Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany
by Alan Brennan & Roberta Ara & Raimund Sterz & Bernd Matiba & Rito Bergemann - 285-289 Tests of stationarity and cointegration of health care expenditure and gross domestic product
by Halil Kiymaz & Yasemin Akbulut & Ahmet Demir - 290-296 Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany
by W. Greiner & K. Lehmann & S. Earnshaw & C. Bug & R. Sabatowski
September 2006, Volume 7, Issue 3
- 155-157 Risk-sharing agreements for innovative drugs
by Gérard Pouvourville - 158-164 Nonmedical economic consequences attributable to visual impairment
by Antoine Lafuma & Antoine Brezin & Francis Fagnani & Viviane Mimaud & Mounir Mesbah & Gilles Berdeaux - 165-172 A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany
by Stephen Beard & Fiona Maciver & Johannes Clouth & Eckart Rüther - 173-178 Test-retest reliability of willingness to pay
by Alan Shiell & Penelope Hawe - 179-184 The costs of schizophrenia in Spain
by Juan Oliva-Moreno & Julio López-Bastida & Rubén Osuna-Guerrero & Angel Montejo-González & Beatriz Duque-González - 185-191 Health care in the CIS countries
by Anatoly Pilyavsky & Matthias Staat - 192-194 Problems and costs associated with alcohol and drug abuse in emergency medicine
by F.-X. Huber & T. Hackert & P. Meeder - 195-203 Determinants of household health expenditure on western institutional health care
by Tin Su & Subhash Pokhrel & Adjima Gbangou & Steffen Flessa - 204-211 Price regulation and generic competition in the pharmaceutical market
by Dag Dalen & Steinar Strøm & Tonje Haabeth - 212-217 Alcohol-related mortality, drinking behavior, and business cycles
by Edvard Johansson & Petri Böckerman & Ritva Prättälä & Antti Uutela - 218-220 Decision models in the evaluation of psychotropic drugs
by Corrado Barbui & Camilla Lintas
July 2006, Volume 7, Issue 2
- 5-13 Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Bengt Jönsson - 14-23 Costs and quality of life of multiple sclerosis in Austria
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Carlotta Plesnilla & Ulf Baumhackl & Thomas Berger & Harald Kolleger & Karl Vass - 24-33 Costs and quality of life for patients with multiple sclerosis in Belgium
by Gisela Kobelt - 34-44 Costs and quality of life of multiple sclerosis in Germany
by Gisela Kobelt & Jenny Berg & Peter Lindgren & W. Elias & P. Flachenecker & M. Freidel & N. König & V. Limmroth & E. Straube - 45-54 Costs and quality of life of multiple sclerosis in Italy
by Gisela Kobelt & Jenny Berg & Peter Lindgren & M. Battaglia & C. Lucioni & A. Uccelli - 55-64 Costs and quality of life in multiple sclerosis in The Netherlands
by Gisela Kobelt & J. Berg & P. Lindgren - 65-74 Costs and quality of life of multiple sclerosis in Spain
by Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado - 75-85 Costs and quality of life of multiple sclerosis in Sweden
by Jenny Berg & P. Lindgren & Sten Fredrikson & Gisela Kobelt - 86-95 Costs and quality of life of multiple sclerosis in Switzerland
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Andrea Gerfin & J. Lutz - 96-104 Costs and quality of life of multiple sclerosis in the United Kingdom
by Gisela Kobelt & Jenny Berg & P. Lindgren & J. Kerrigan & N. Russell & R. Nixon
July 2006, Volume 7, Issue 02
- 5-13 Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Bengt Jönsson - 14-23 Costs and quality of life of multiple sclerosis in Austria
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Carlotta Plesnilla & Ulf Baumhackl & Thomas Berger & Harald Kolleger & Karl Vass - 24-33 Costs and quality of life for patients with multiple sclerosis in Belgium
by Gisela Kobelt - 34-44 Costs and quality of life of multiple sclerosis in Germany
by Gisela Kobelt & Jenny Berg & Peter Lindgren & W. Elias & P. Flachenecker & M. Freidel & N. König & V. Limmroth & E. Straube - 45-54 Costs and quality of life of multiple sclerosis in Italy
by Gisela Kobelt & Jenny Berg & Peter Lindgren & M. Battaglia & C. Lucioni & A. Uccelli - 55-64 Costs and quality of life in multiple sclerosis in The Netherlands
by Gisela Kobelt & J. Berg & P. Lindgren - 65-74 Costs and quality of life of multiple sclerosis in Spain
by Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado - 75-85 Costs and quality of life of multiple sclerosis in Sweden
by Jenny Berg & P. Lindgren & Sten Fredrikson & Gisela Kobelt - 86-95 Costs and quality of life of multiple sclerosis in Switzerland
by Gisela Kobelt & Jenny Berg & Peter Lindgren & Andrea Gerfin & J. Lutz - 96-104 Costs and quality of life of multiple sclerosis in the United Kingdom
by Gisela Kobelt & Jenny Berg & P. Lindgren & J. Kerrigan & N. Russell & R. Nixon